Literature DB >> 17292047

Consequences of disrupting the dystrophin-sarcoglycan complex in cardiac and skeletal myopathy.

Ahlke Heydemann1, Elizabeth M McNally.   

Abstract

Mutations that disrupt the dystrophin glycoprotein complex lead to plasma membrane instability of cardiomyocytes and skeletal muscle myofibers. Instability of the plasma membrane leads to degeneration largely due to activation of a necrotic process in these disorders. In response to ongoing degeneration, skeletal muscle exhibits robust regeneration while in cardiac muscle regeneration is not obvious. The dystrophin complex is concentrated along the plasma membrane in costameric structures that correspond to the Z bands of sarcomeres, thus positioning the dystrophin complex to transmit force between the sarcomere and the plasma membrane to the extracellular matrix. Although it is apparent that this position is important for perpendicular force transmission, it is clear that the dystrophin complex also fulfills signaling roles. Nitric oxide synthase and stress-induced signaling cascades are activated to participate in protection but may also contribute to pathology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17292047     DOI: 10.1016/j.tcm.2006.12.002

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  37 in total

1.  Worsening of cardiomyopathy using deflazacort in an animal model rescued by gene therapy.

Authors:  Ida Luisa Rotundo; Stefania Faraso; Elvira De Leonibus; Gerardo Nigro; Carmen Vitiello; Alessio Lancioni; Daniele Di Napoli; Sigismondo Castaldo; Vincenzo Russo; Fabio Russo; Giulio Piluso; Alberto Auricchio; Vincenzo Nigro
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

2.  Genome-wide Mechanosensitive MicroRNA (MechanomiR) Screen Uncovers Dysregulation of Their Regulatory Networks in the mdm Mouse Model of Muscular Dystrophy.

Authors:  Junaith S Mohamed; Ameena Hajira; Michael A Lopez; Aladin M Boriek
Journal:  J Biol Chem       Date:  2015-08-13       Impact factor: 5.157

3.  Delta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters.

Authors:  Masahiko Hoshijima; Takeharu Hayashi; Young E Jeon; Zhenxing Fu; Yusu Gu; Nancy D Dalton; Mark H Ellisman; Xiao Xiao; Frank L Powell; John Ross
Journal:  Circ Heart Fail       Date:  2010-10-29       Impact factor: 8.790

4.  DOT1L regulates dystrophin expression and is critical for cardiac function.

Authors:  Anh T Nguyen; Bin Xiao; Ronald L Neppl; Eric M Kallin; Juan Li; Taiping Chen; Da-Zhi Wang; Xiao Xiao; Yi Zhang
Journal:  Genes Dev       Date:  2011-02-01       Impact factor: 11.361

Review 5.  Progress in gene therapy of dystrophic heart disease.

Authors:  Y Lai; D Duan
Journal:  Gene Ther       Date:  2012-02-09       Impact factor: 5.250

Review 6.  Fluorescence-based force/tension sensors: a novel tool to visualize mechanical forces in structural proteins in live cells.

Authors:  Jun Guo; Frederick Sachs; Fanjie Meng
Journal:  Antioxid Redox Signal       Date:  2014-01-15       Impact factor: 8.401

7.  Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury.

Authors:  Erica C Campos; Minna M D Romano; Cibele M Prado; Marcos A Rossi
Journal:  Int J Exp Pathol       Date:  2008-10       Impact factor: 1.925

Review 8.  Transcriptional networks regulating the costamere, sarcomere, and other cytoskeletal structures in striated muscle.

Authors:  Nelsa L Estrella; Francisco J Naya
Journal:  Cell Mol Life Sci       Date:  2013-11-12       Impact factor: 9.261

9.  Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy.

Authors:  Nalinda B Wasala; Brian Bostick; Yongping Yue; Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2013-03-03       Impact factor: 6.150

10.  Serial examination of an inducible and reversible dilated cardiomyopathy in individual adult Drosophila.

Authors:  Il-Man Kim; Matthew J Wolf
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.